Suscribirse

Persistent carbapenem resistance in mechanically ventilated ICU patients: A before-and-after analysis of the COVID-19 surge - 24/02/25

Doi : 10.1016/j.ajic.2024.10.014 
Bianca B.P. Antunes, PhD a, Leonardo S.L. Bastos, PhD a, Pedro Kurtz, PhD b, c, d, Letícia M. Sant’Anna, BSc a, Pedro F. del Peloso, PhD b, e, Claudia A. Espanha, MS b, f, Silvio Hamacher, PhD a, Fernando A. Bozza, MD, PhD b, g, h,
a Department of Industrial Engineering, Pontifical Catholic University of Rio de Janeiro (PUC-Rio), Rio de Janeiro, Rio de Janeiro, Brazil 
b Department of Critical Care, D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil 
c Intensive Care Department, Copa Star Hospital, Rio de Janeiro, Rio de Janeiro, Brazil 
d Intensive Care Department, Paulo Niemeyer State Brain Institute (IECPN), Rio de Janeiro, Rio de Janeiro, Brazil 
e Laboratory of Clinical Microbiology, Richet Laboratory, Rio de Janeiro, Brazil 
f Hospital Infection Control Comittee, Clínica São Vicente, Rio de Janeiro, Rio de Janeiro, Brazil 
g National Institute of Infectious Disease Evandro Chagas (INI), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil 
h Comprehensive Health Research Centre (CHRC), NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal 

Address correspondence to Fernando A. Bozza, MD, PhD, Instituto Nacional de Infectologia Evandro Chagas (INI), FIOCRUZ, Av Brasil 4365, Manguinhos, Rio de Janeiro, RJ 21045-900, Brazil.Instituto Nacional de Infectologia Evandro Chagas (INI), FIOCRUZAv Brasil 4365, ManguinhosRio de JaneiroRJ21045-900Brazil

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Resumen

Background

The evolution of antimicrobial resistance among critically ill patients before, during, and after the COVID-19 surge remains unclear.

Methods

We retrospectively analyzed critically ill mechanically ventilated adult patients admitted to 8 Brazilian hospitals from Jan 1, 2018 to Apr 30, 2023. We stratified the patients into 3 periods: pre-surge (Jan 01, 2018-Mar 01, 2020), surge (Mar 01, 2020-Oct 01, 2021), and post-surge (after October 01, 2021). Positive cultures, pathogen prevalence, and resistance rates were analyzed using rate ratios (RR) with 95% confidence intervals (CI).

Results

Among 9,780 patients (3,718 pre-surge, 3,815 surge, 2,247 post-surge), those in surge period were younger (median: 70 vs 74 pre-surge vs 75 post surge) and had longer invasive mechanical ventilation duration (median 7 vs 5 days). Blood and respiratory cultures increased across periods (56.9 pre-surge vs 69.4 surge vs 70.4 patients/1,000 patient-days post-surge). Isolation of carbapenem-resistant gram-negatives increased during the surge (RR [95% CI]: 1.8 [1.5-2.2], decreased in post-surge (0.72 [0.6-0.9]), and remained higher than pre-surge (1.3 [1.0-1.6]). Resistance rates for Pseudomonas aeruginosa reduced in post-surge, whereas Klebsiella pneumoniae doubled during the surge, and remained elevated.

Conclusions

Carbapenem resistance increased during the surge period. Although it decreased post-surge, it remained higher than pre-pandemic rates.

El texto completo de este artículo está disponible en PDF.

Highlights

9,780 ventilated patients: 3,718 pre-COVID-19 surge, 3,815 surge, 2,247 post-surge.
Carbapenem resistance rose during surge and stayed higher post-surge than pre-surge.
Gram-negative isolation stayed high post-surge, Candidemia and MRSA showed no change.
Stewardship programs must adapt, ensuring antimicrobial consumption control.

El texto completo de este artículo está disponible en PDF.

Key Words : Antimicrobial resistance, Intensive Care Unit, Coronavirus, Antibiotic


Esquema


 Funding/support: This work was supported by CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), and Department of Science and Technology (DECIT) from the Brazilian Ministry of Health (grant number: 444968/2023-7); FAPERJ (Fundação Carlos Chagas Filho de Amparo à Pesquisa do Rio de Janeiro); CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior)---Finance Code 001; and Pfizer Global Medical Grants and Global Bridges at Mayo Clinic (grant number 69832333).
 Conflicts of interest: None to report.


© 2024  Association for Professionals in Infection Control and Epidemiology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 53 - N° 3

P. 320-325 - mars 2025 Regresar al número
Artículo precedente Artículo precedente
  • The patterns of antifungal use and risk factors associated with mortality in patients with invasive candidiasis and aspergillosis infections among patients who were received infectious disease specialist consultation prior to and during the COVID-19 pandemic in a resource-limited setting: A retrospective cohort study
  • Supavit Vaivoothpinyo, Kittiya Jantarathaneewat, David J. Weber, Bernard C. Camins, Piyaporn Apisarnthanarak, Sasinuch Rutjanawech, Anucha Apisarnthanarak
| Artículo siguiente Artículo siguiente
  • Elizabethkingia meningoseptica in Dubai, United Arab Emirates: A 7-year multicenter study
  • Hawra Ali Hussain Alsayed, Narjes Saheb Sharif-Askari, Fatemeh Saheb Sharif-Askari, Rabih Halwani

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.